What Vyvgart treats
Vyvgart (efgartigimod alfa-fcab) is a biologic therapy approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. It is the first-in-class neonatal Fc receptor (FcRn) blocker, designed to reduce the levels of pathogenic autoantibodies that cause muscle weakness in patients with myasthenia gravis.
Benefits of Vyvgart
The treatment goals for patients prescribed Vyvgart include:
- Reduced muscle weakness
- Improved ability to perform daily activities
- Enhanced breathing, swallowing, and mobility
- Symptom control
Vyvgart reduces circulating IgG, including the pathogenic autoantibodies associated with gMG.
Possible Side Effects of Vyvgart
Common side effects may include:
- Respiratory tract infections
- Headache
- Urinary tract infections
- Fatigue
Serious side effects may include:
- Increased risk of infections due to reduced antibody levels
- Hypersensitivity or allergic reactions
Patients are monitored during and after infusions, and treatment cycles are spaced to minimize risk and maintain clinical benefit.
How infusion works at Prime
Vyvgart is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Vyvgart, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Vyvgart Work?
Vyvgart works by blocking the neonatal Fc receptor (FcRn), which plays a role in protecting IgG antibodies from degradation. In patients with gMG, harmful autoantibodies attack the communication between nerves and muscles. By inhibiting FcRn, Vyvgart accelerates the breakdown of these pathogenic antibodies, reducing their levels in the blood and relieving symptoms of muscle weakness. It is administered through intravenous infusion, typically once weekly for four weeks, with subsequent cycles based on clinical response.
Who is Vyvgart For?
Vyvgart is indicated for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies. It is intended for patients experiencing moderate to severe symptoms who require additional treatment beyond standard therapies such as cholinesterase inhibitors, corticosteroids, or other immunosuppressants.